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. The CREB family of activators regulates a striking number of physiologic processes including intermediary metabolism, cell cycle control, cellular proliferation, cell survival-death decisions, and neuronal signaling by altering basic patterns of CRE-dependent gene expression (Montminy, 1997) . CREB-1 binds to DNA as a homodimer via a carboxy-terminal basic region/leucine zipper (bZIP) motif (Dwarki et al., 1990 ) that is conserved in several nuclear factors including ATF-2, jun, fos and myc (Landschulz et al., 1988) . CREB family members are activated by phosphorylation in response to a number of signaling pathways, including cAMP, calcium, stress and mitogenic stimuli (Montminy, 1997) .
As mentioned above, phosphorylation of CREB family proteins at Ser133 in response to a cAMP stimulus induces target gene expression. Phosphorylated (Ser133) CREB-1 binds directly to CBP and its paralogue p300. In turn, CBP and p300 mediate transcriptional induction via their physical association with RNA polymerase II holoenzyme complexes (Montminy, 1997) .
Reduced folates are vitamins necessary for one-carbon transfer reactions resulting in the de novo biosynthesis of nucleotides and amino acids (Stockstad, 1990) . However, as mammalian cells are devoid of tetrahydrofolate biosynthesis, these cofactors are taken up into mammalian cells primarily by the reduced folate carrier (RFC) 1 (Matherly and Goldman, 2003; Jansen and Pieters, 1998) . Moreover, RFC is the dominant transporter for antifolates including methotrexate (MTX), raltitrexed (Tomudex) (Jackman et al., 1991) and pemetrexed (multitargeted antifolate, MTA) (Shih et al., 1997) . MTX is used in the treatment of various human malignancies, whereas raltitrexed and pemetrexed have been recently approved for the treatment of advanced colorectal cancer and malignant pleural mesothelioma, respectively (reviewed in Van Custem et al., 2002; Manegold, 2003, respectively) . This article has not been copyedited and formatted. The final version may differ from this version.
Molecular Pharmacology Fast Forward. Published on August 31, 2004 as DOI: 10.1124 at ASPET Journals on June 21, 2017 molpharm.aspetjournals.org
Downloaded from

MOL # 4135R
However, inherent and acquired drug resistance are major obstacles towards curative cancer chemotherapy (Matherly and Goldman, 2003; Jansen and Pieters, 1998) . One predominant mechanism of antifolate resistance in vitro and in vivo is impaired drug transport (reviewed in Jansen and Pieters, 1998; Zhao and Goldman, 2003) . For example, inactivating mutations in the hRFC gene were detected in antifolate-resistant tumor cell lines (Gong et al., 1997; Wong et al., 1999; Drori et al., 2000; Rothem et al., 2002) , in acute lymphoblastic leukemia (ALL) (Kaufman et al., 2004) , and in osteosarcoma patients (Yang et al., 2003) .
Recently we have identified a novel mechanism of impaired antifolate transport that is based on the loss of hRFC gene expression in antifolate-resistant cell lines; this was due to transcriptional silencing resulting from loss of expression and/or function of various transcription factors (Rothem et al., 2003; Rothem et al., 2004) . Specifically, decreased binding (or loss) of various transcription factors to CRE, GC-box, Mzf-1, AP-1 and E-box consensus sites in the hRFC promoter was detected in 50-80% of the antifolate-resistant cell lines. This was primarily due to decreased expression and/or function of the cognate transcriptional activators. Furthermore, two thirds of the antifolate-resistant cell lines displayed a marked decrease in transcription factor binding to a single CRE site present in the minimal promoter A of the hRFC gene (Rothem et al., 2004) ; this was associated with a profound decrease in pCREB-1 levels. Here we explored the molecular basis for the loss of pCREB-1 and CREbinding in these antifolate-resistant cells. We find a markedly impaired phosphorylation of CREB-1 in these drug-resistant variants. Remarkably, various agents that augment intracellular cAMP levels restored CREB-1 phosphorylation, CRE-binding and CRE-dependent reporter gene activity. This consequently resulted in restoration of CREB-1 and hRFC gene expression.
Using various agonists along the cAMP signaling pathway we propose that the CREB-1 phosphorylation defect is possibly due to an impaired activity of Gαs subunits or their coupled This article has not been copyedited and formatted. The final version may differ from this version. 
receptors. However, further studies will be necessary to identify the specific lesion in this cAMP-PKA signaling pathway.
Materials and Methods
Drugs: MTX, aminopterin, dibutyryl cAMP, 3-isobuty-1-methylxanthine, forskolin and cholera toxin were from Sigma. Novel antifolate drugs were generous gifts from the following sources: AG2034, Dr. T. Boritzki (Agouron Pharmaceuticals, Inc.); PT523, Dr. W.T.
McCulloch (Sparta Pharmaceuticals) and ZD9331, Dr. A. Jackman, (Institute of Cancer Research, Sutton, UK).
Cell Lines and Tissue Culture: CCRF-CEM, a human T-cell leukemia line and its antifolateresistant sublines (Rothem et al., 2002; Rothem et al., 2004) (Rothem et al., 2002) .
Electrophoretic Mobility Shift Assays:
Nuclear extracts were prepared from exponentially growing cells (2 x10 7 cells) as previously described (Schreiber et al., 1989) . DNA-protein complexes were formed by incubating nuclear extract proteins (6 µ g) with [α-32 P]dCTP endlabeled CRE double-stranded oligonucleotides as detailed elsewhere (Ohlsson and Edlund, 1986) . Protein concentration was determined by the colorimetric method of Bradford (1976) .
Semi-quantitative RT-PCR Analysis of CREB-1 and RFC Expression:
Cells (1x10 7 ) from the mid-log phase of growth were harvested by centrifugation, washed with PBS and total RNA was isolated using the Tri-Reagent kit according to the instructions of the manufacturer (Sigma). A portion of total RNA (20 µ g in a total volume of 20 µ l) was reverse transcribed This article has not been copyedited and formatted. The final version may differ from this version. from parental cells and their antifolate-resistant sublines were amplified using 10 pmols of each primer in 2xReddyMix PCR master mix reaction buffer according to the instructions of the manufacturer (ABgene, Surrey, UK). The PCR reaction was performed as follows: initial melting at 95 o C for 5 min, followed by 30 cycles each of 1 min at 95 o C, annealing at 60 o C for 45 seconds, elongation at 72 o C for 1 min, followed by 10 min extension at 72 o C. Then, the PCR products were resolved on 2% agarose gels containing ethidium bromide. The primers used for the semi-quantitative RT-PCR of RFC and GAPDH were previously described (Rothem et al., 2003) . Semi-quantitative RT-PCR analysis of CREB-1 was performed as described above for RFC, using the forward primer: 5'-CCCAGCCATCAGTTATTCAG-3' and the reverse primer 5'-GAGTTGGCACCGTTACAGTG-3'.
Transient Transfections with Expression Constructs and Reporter Gene Activity:
Exponentially growing suspension cells (2x10 7 ) were harvested by centrifugation and transiently transfected by electroporation (1000 µ F, 234 V) with 10 µ g of the following
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(Promega) and a luminometer. Results presented were obtained from at least three independent transient transfections performed in duplicate cultures. 
(w/v) glycerol, 0.5% dithiothreitol and 0.1% bromophenol blue. Then, in order to achieve carbamoylmethylation, the gel strips were re-equilibrated for 15 min in the same buffer containing 2% iodacetamide in place of dithiothreitol. The second-dimension separation was carried out by placing the strips on Criterion 4-20% polyacrylamide gels, following which gels were electroblotted onto Protran BA83-cellulose nitrate membranes (Schleicher and Schuell) and reacted with antibodies as described above.
Results
Decreased CREB-1 mRNA levels and restoration by forskolin in antifolate-resistant cell lines: Recently we have shown that multiple antifolate-resistant tumor cell lines with impaired drug transport display markedly decreased pCREB-1 levels and a poor CRE-binding (Rothem et al., 2003; Rothem et al., 2004) . As pCREB-1 is the transcriptionally active species, we here studied the mechanism underlying the marked decrease in pCREB-1 levels in these cell lines.
Since CREB-1 gene expression is a subject for auto-regulation by pCREB-1 itself (Montminy, 1997) , CREB-1 mRNA levels were first determined by semi-quantitative RT-PCR analysis (Fig 1) . The antifolate-resistant cell lines displayed barely detectable levels of CREB-1 mRNA when compared to their parental cells. Remarkably, 2 hr treatment of these cell lines with 20 µ M forskolin, a potent activator of adenylyl cyclase (AC) that induces an increase in intracellular cAMP levels, resulted in restoration of CREB-1 mRNA levels (Fig 2) .
Furthermore, transient transfection of these antifolate-resistant cell lines with an expression construct harboring a constitutively transcriptionally active CREB-1 derivative (i.e. VP16-CREB-1) also resulted in high CREB-1 mRNA levels (Fig 2) .
Two-dimensional Western analysis of pCREB-1 species before and after treatment with forskolin: As mentioned above, since pCREB-1 is the transcriptionally active form, we determined the relative distribution of the non-phosphorylated CREB-1 and its phosphoisotypes using Western analysis after high-resolution 2-dimensional gel electrophoresis (2-DGE; Fig 3) . Equal amounts of nuclear proteins were first separated by isoelectric focusing on an immobilized pH 3-10 gradient. Resolved proteins were subsequently separated by SDS-PAGE in the second dimension, transferred to nylon membranes and analyzed by Western analysis using an anti-CREB-1 antibody. Parental cells expressed prominent levels of the 43 kDa non-phosphorylated CREB-1 protein (Fig 3A, arrowhead) along with several pCREB-1 This article has not been copyedited and formatted. The final version may differ from this version. 
MOL # 4135R
species that showed both increasing acidity and a slightly increasing molecular mass (Fig 3A, arrows). In contrast, antifolate-resistant cells (shown is an example of AG2034 R2 cells), expressed poor levels of both CREB-1 (Fig 3B, arrowhead) and its more acidic pCREB-1 species (Fig 3B, arrows) . Consistent with the RT-PCR results, treatment of AG2034 R2 cells for 2 hr with 20 µ M forskolin, an activator of AC that increases intracellular cAMP levels, resulted in a complete restoration of both parental CREB-1 levels (Fig 3C, arrowhead) as well as of the various phosphoisotypes of CREB-1 (Fig 3C, arrows) .
Western analysis of pCREB-1 levels before and after treatment with various cAMP reactive agents: The above findings with forskolin-treated AG2034 R2 cells upon 2-DGE were corroborated with the various antifolate-resistant cell lines using an antibody to pCREB-1.
First, pCREB-1 levels were determined in the various antifolate-resistant cell lines by Western analysis with an antibody to pCREB-1 before and after treatment with forskolin (Fig 4) . In concordance with the 2-DGE results, pCREB-1 levels were nearly undetectable in the various antifolate-resistant cell lines when compared to parental cells. However, 2 hr treatment of these drug-resistant cell lines with forskolin resulted in a dramatic restoration of pCREB-1 levels, sometimes exceeding parental levels (Fig 4A) . Consistent with the effect of forskolin, we used various agents along the PKA pathway that augment intracellular cAMP including dibutyryl cAMP (Bt 2 cAMP), a cell-permeable cAMP analogue; 3-isobutyl-1-methylxanthine (IBMX), an effective inhibitor of cAMP hydrolysis; cholera toxin (CTX), a most upstream agonist which renders the Gαs subunit constitutively active. Three hr treatment of antifolate-resistant cells with 1mM Bt 2 cAMP, 0.5 µ g/ml CTX (Fig 4B, lower panel 
restoration of parental CREB mRNA levels (Fig 2) but failed to restore wild type pCREB-1 levels (Fig 4B, compare lanes 6,10,14 and 18 with lanes 1,2). Reprobing with antibodies to AP2α, a transcription factor that was retained at normal levels in all antifolate-resistant cell lines (Rothem et al., 2004) , confirmed that identical amounts of nuclear proteins were being analyzed (Fig 4B, upper panel) . Moreover, total cell proteins were extracted from non-treated parental and antifolate-resistant cell lines, resolved by electrophoresis, transferred to nylon membranes and reacted with an antibody to PKA (RIIα), the cAMP-dependent kinase responsible for CREB-1 phosphorylation; this revealed identical PKA levels in the various antifolate-resistant cell lines (Fig 4C) .
Restoration of CRE-binding and CRE-dependent reporter gene activity by cAMPaugmenting agents:
Since treatment of antifolate-resistant cells with various cAMPaugmenting agents resulted in restoration of both CREB and pCREB-1 levels (Fig 3 and Fig   4A,B) , we examined whether CRE-binding and CRE-luciferase activity was also restored.
Indeed, treatment with forskolin resulted in a marked restoration of CRE-binding (Fig 5) .
Furthermore, the poor pCREB-1 levels (Fig 3 and Fig 4A,B) and the profoundly decreased CRE-binding (Fig 5) in the various antifolate-resistant cell lines were consistently reflected in a markedly diminished CRE-dependent luciferase reporter activity, thus displaying levels as low as 7.7% of parental cells' activity (Fig 6) . Remarkably, 2-3 hr treatment of these drug-resistant cell lines with the various cAMP-augmenting agents, 21-22 hr after transient transfection with a CRE-luciferase reporter construct, resulted in a dramatic restoration of reporter gene activities (Fig 6) ; for example, after treatment with forskolin, antifolate-resistant cell lines displayed up to 295% of parental luciferase activity. Consistently, transient transfection of parental cells with an expression construct harboring a constitutively transcriptionally active CREB-1 form (VP16-CREB-1) did not result in any increase in CRE-driven luciferase activity. 
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In contrast, antifolate-resistant cell lines transiently transfected with this construct displayed a 9-53-fold increase in reporter gene activity since VP16-CREB-1 is constitutively active in transcription even in the absence of phosphorylation (Fig 6) . These results establish that agents that augment cellular cAMP levels induce restoration of CRE-dependent gene expression in the various antifolate-resistant cell lines.
Restoration of hRFC gene expression in antifolate-resistant cell lines by treatment with
forskolin and transfection with VP-16-CREB-1: Previously we have shown that various antifolate-resistant cell lines were impaired in antifolate transport (Rothem et al., 2002) due to a prominent decrease or complete loss of hRFC gene expression (Rothem et al., 2003; Rothem et al., 2004) . Consistently here, semi-quantitative RT-PCR analysis corroborated these findings of the decrease or loss of RFC mRNA levels in these antifolate-resistant cell lines (Fig 7) .
Furthermore, treatment with forskolin which restored pCREB-1 levels (Fig 3 and Fig 4A,B) resulted in a partial or complete restoration of hRFC gene expression in the various antifolateresistant cell lines. Consistently, introduction of the constitutively transcriptionally active VP16-CREB-1 construct into these antifolate-resistant cells also resulted in a complete restoration parental RFC mRNA levels.
This article has not been copyedited and formatted. The final version may differ from this version. 
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Discussion
There is increasing evidence to suggest that binding of pCREB-1 to CRE in the hRFC promoter 
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auto-regulatory mechanism, thereby resulting in restoration of newly synthesized CREB-1 and pCREB-1 levels. Third, transient transfection of the various antifolate-resistant cell lines with VP16-CREB-1 had only a minor effect (i.e. increase) on pCREB-1 levels. The ectopically overexpressed VP16-CREB-1 could readily bind to CRE consensus sequences and thereby restore CRE-luciferase reporter activity in the various antifolate-resistant cell lines. This consequently resulted in resumption of wild type CREB-1 mRNA levels. However, as these drug-resistant cell lines were defective in PKA-dependent phosphorylation, VP16-CREB-1 overproduction failed to restore substantial pCREB-1 levels.
The following evidence suggest that the markedly decreased phosphorylation of CREB-1 in the various antifolate-resistant cell lines is due to an upstream signaling defect in the cAMP-PKA pathway presumably at the level of the Gαs subunits and/or or their G-proteincoupled receptors. In order to explore the mechanism underlying the defect of CREB-1 phosphorylation, we undertook a series of experiments that examined various steps in the PKA signaling pathway. To this end, we used several agents that target various enzymes in the PKA pathway and thereby directly or indirectly result in augmentation of intracellular cAMP levels (summarized in Fig 8) . These include Bt 2 cAMP, a cell-permeable cAMP analogue that mimics the action of endogenous cAMP and also has a greater resistance to hydrolysis by cAMP phosphodiesterases; IBMX, an effective inhibitor of phosphodisterases with subsequent inhibition of cyclic nucleotide hydrolysis resulting in increased intracellular cAMP pools;
forskolin, a potent activator of AC that brings about a marked synthesis of cAMP; and finally cholera toxin, an upstream agonist that catalyzes the ADP-ribosylation of Gαs subunits of Gproteins that are coupled to various receptors, and by doing so prevents the hydrolysis of GTP to GDP, thereby resulting in constitutively active Gαs subunits. Two-three hr treatment of the various antifolate-resistant cells with these agents restored CRE-binding, CREB-1 mRNA, 
CREB-1 and pCREB-1 protein levels, as well as CRE-luciferase activity. Since cholera toxin is the most upstream agent used here, we conclude that the defect in the PKA pathway is presumably at the level of Gαs or even more upstream at the level of the G-protein coupled receptors. The fact that antifolate-resistant cell lines maintained normal levels of PKA, the enzyme that directly phosphorylates CREB-1 along with the finding that fosrkolin, a potent activator of AC resulted in restoration of CREB-1 phosphorylation strongly attest that the CREB-1 phosphorylation defect is indeed upstream to PKA and AC.
Previous studies have clearly established that phosphorylation of Ser133 is a prerequisite for the conversion of CREB-1 to a transcriptional transcativator (Montminy, 1997) . In this respect, induction of PKA activity in cultured glioma cells with the β adrenoreceptor agonist isoproterenol resulted in increased phosphorylation of CREB-1; highresolution 2-DGE revealed that pCREB-1 had a pI of 4.6 (Storm and Khawaja, 1999) . Using high-resolution 2-DGE we consistently find here that forskolin-treatment of antifolate-resistant cells resulted in increased CREB-1 phosphorylation with an initial pI of ~ 4.5. However, we note that parental CCRF-CEM cells as well as forskolin-treated antifolate-resistant cells contained several phosphoisotypes of CREB-1 that became more acidic upon further phosphorylation after forskolin activation. This phenomenon that hyperphosphorylation renders proteins more acidic has been recently observed with various proteins including for example the p21-activated kinase 1 (Pak1) (Kissil et al., 2003) ; in this study, the effect of merlin 
presumably other family members including CREB-1 at multiple serine and threonine sites other than Ser133 (DeGroot et al., 1993) . Furthermore, stimulation by forskolin of various transduction pathways including the cAMP-PKA pathway results in enhanced phosphorylation of Ser117, concomitant with an increase in the transactivation potential. b) Ser129, a consensus phosphoacceptor site for glycogen synthase kinase-3 (GSK-3) has been proposed to regulate CREB-1 activity in conjunction with Ser133 following cAMP induction (Fiol et al., 1994) .
Indeed, PKA-mediated phosphorylation of CREB-1 at ser 133 appears to promote GSK-3mediated phosphorylation of Ser129. Importantly, site-directed substitution of Ser129 to Ala resulted in impairment of CREB-1 activity in PC12 cells, suggesting that Ser129 may contribute to CREB-1 activity. These authors therefore proposed that the hierarchical phosphorylation of CREB-1 at the PKA (i.e. Ser133) and GSK-3 (i.e. Ser129) sites are essential for the cAMP control of CREB-1 activity. c) Consistent with the above results Enslen et al. (1994) reported that CREB-1 undergoes phosphorylation at Ser133 as well as at a site independent of Ser133 and Ser 98 by a Ca 2+ /Calmodulin-dependent protein kinase IV. Hence, CREB-1 and other transactivators of the CRE family can undergo phosphorylation at several sites other than Ser133.
In summary, in the current paper we have shown that transport-impaired, antifolate-resistant cell lines exhibit a cAMP-dependent phosphorylation defect. Following dissection of the PKA signaling pathway with various downstream and upstream agents that augment intracellular cAMP levels we conclude that the phosphorylation defect is possibly at the level of Gαs subunits and/or their G-protein coupled receptors. Clearly, further studies will be necessary in order to identify the specific lesion in this cAMP-PKA signaling pathway.
This article has not been copyedited and formatted. The final version may differ from this version. Nuclear proteins (100 µ g) isolated from untreated parental (A) and antifolate-resistant AG2034 R2 cells (B) as well as forskolin-treated AG2034 R2 cells (C) were subjected to highresolution 2-DGE. Then, the blots were reacted with antibodies to CREB-1 in order to detect non-phosphorylated (arrowhead) as well as the phoshorylated species of CREB-1 (arrows).
Note that the non-phosphorylated CREB-1 had a molecular mass of ~43 kDa and an apparent pI of ~ 4.5, whereas the increasing phosphorylation levels of CREB-1 resulted in a consistent increase in the molecular mass along with an increasing acidity (i.e. decreasing pI). 1 (A, B) . Western blots were then reprobed with an antibody to AP2α (B). Total cell proteins were extracted from the various cell lines before treatment, resolved by electrophoresis, transferred to nylon membranes and reacted with an antibody to PKA RIIα (C) as detailed in Materials and Methods. 
